XHKG8357
Market cap5mUSD
Dec 23, Last price
0.07HKD
1Q
9.09%
IPO
-89.41%
Name
Republic Healthcare Ltd
Chart & Performance
P/E
—
P/S
0.79
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
6.25%
Rev. gr., 5y
-0.82%
Revenues
10m
+10.65%
Net income
-855k
L-41.76%
CFO
900k
P
Earnings
Jun 20, 2025
Profile
Republic Healthcare Limited, a primary healthcare services company, provides consultation, medical investigation, and treatment services in Singapore. The company offers various treatment solutions for common medical conditions and focuses on sexual health and infectious diseases. It also provides treatment solutions for common skin conditions and basic medical aesthetics services. The company operates nine clinics under the Dr. Tan & Partners brand name; and one clinic under the S Aesthetics brand name. Republic Healthcare Limited was founded in 2010 and is headquartered in Singapore.
Valuation
Title SGD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 10,002 10.65% | 9,040 -32.37% | 13,366 -2.61% | |||||
Cost of revenue | 3,994 | 3,444 | 5,445 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | 6,008 | 5,596 | 7,921 | |||||
NOPBT Margin | 60.07% | 61.91% | 59.26% | |||||
Operating Taxes | 27 | 28 | (20) | |||||
Tax Rate | 0.45% | 0.51% | ||||||
NOPAT | 5,981 | 5,568 | 7,941 | |||||
Net income | (855) -41.76% | (1,468) 47.14% | (998) -1,614.27% | |||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 3,632 | |||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | 490 | 428 | 812 | |||||
Long-term debt | 1,432 | 1,193 | 2,287 | |||||
Deferred revenue | ||||||||
Other long-term liabilities | 135 | 149 | 214 | |||||
Net debt | (10,153) | (10,214) | (11,046) | |||||
| Cash flow | ||||||||
Cash from operating activities | 900 | (734) | (510) | |||||
CAPEX | (83) | (423) | (620) | |||||
Cash from investing activities | 831 | (987) | (1,557) | |||||
Cash from financing activities | (588) | (690) | 2,275 | |||||
FCF | 6,472 | 6,101 | 9,248 | |||||
| Balance | ||||||||
Cash | 12,076 | 11,835 | 14,145 | |||||
Long term investments | ||||||||
Excess cash | 11,576 | 11,383 | 13,477 | |||||
Stockholders' equity | (1,315) | 50 | 1,526 | |||||
Invested Capital | 15,163 | 14,946 | 15,777 | |||||
ROIC | 39.73% | 36.24% | 54.45% | |||||
ROCE | 43.39% | 37.30% | 45.76% | |||||
| EV | ||||||||
Common stock shares outstanding | 624,000 | 624,000 | 550,773 | |||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | 6,812 | 6,607 | 9,784 | |||||
EV/EBITDA | ||||||||
Interest | 54 | 57 | 118 | |||||
Interest/NOPBT | 0.90% | 1.02% | 1.49% | |||||